tetano
Editor, Senior Moderator
Am J Physiol Cell Physiol
. 2020 Jun 9.
doi: 10.1152/ajpcell.00187.2020. Online ahead of print.
H [SUB]2[/SUB] S as a Potential Defence Against COVID-19?
Guangdong Yang[SUP] 1 [/SUP]
Affiliations
Abstract
The outbreak of COVID-19 pneumonia caused by a new coronavirus (SARS-CoV-2) is posing a global health emergency and has led to more than 380,000 deaths worldwide. The cell entry of SARS-CoV-2 depends on two host proteins angiotensin-converting enzyme 2 (ACE2) and TMPRSS2. There is currently no vaccine available and also no effective drug for the treatment of COVID-19. Hydrogen sulfide (H[SUB]2[/SUB]S) as a novel gasotransmitter has been shown to protect against lung damage via its anti-inflammation, anti-oxidative stress, anti-viral, pro-survival, and anti-aging effects. In light of the research advances on H[SUB]2[/SUB]S signalling in biology and medicine, this review proposed H[SUB]2[/SUB]S as a potential defence against COVID-19. It is suggested that H[SUB]2[/SUB]S may block SARS-CoV-2 entry into host cells by interfering with ACE2 and TMPRSS2, inhibit SARS-CoV-2 replication by attenuating virus assembly/release, and protect SARS-CoV-2-induced lung damage by suppressing immune response and inflammation development. Preclinical studies and clinical trials with slow-releasing H[SUB]2[/SUB]S donor(s) or the activators of endogenous H[SUB]2[/SUB]S-generating enzymes should be considered as a preventative treatment or therapy for COVID-19.
Keywords: ACE2; COVID-19; H2S; SARS-CoV-2; TMPRSS2.
. 2020 Jun 9.
doi: 10.1152/ajpcell.00187.2020. Online ahead of print.
H [SUB]2[/SUB] S as a Potential Defence Against COVID-19?
Guangdong Yang[SUP] 1 [/SUP]
Affiliations
- PMID: 32515982
- DOI: 10.1152/ajpcell.00187.2020
Abstract
The outbreak of COVID-19 pneumonia caused by a new coronavirus (SARS-CoV-2) is posing a global health emergency and has led to more than 380,000 deaths worldwide. The cell entry of SARS-CoV-2 depends on two host proteins angiotensin-converting enzyme 2 (ACE2) and TMPRSS2. There is currently no vaccine available and also no effective drug for the treatment of COVID-19. Hydrogen sulfide (H[SUB]2[/SUB]S) as a novel gasotransmitter has been shown to protect against lung damage via its anti-inflammation, anti-oxidative stress, anti-viral, pro-survival, and anti-aging effects. In light of the research advances on H[SUB]2[/SUB]S signalling in biology and medicine, this review proposed H[SUB]2[/SUB]S as a potential defence against COVID-19. It is suggested that H[SUB]2[/SUB]S may block SARS-CoV-2 entry into host cells by interfering with ACE2 and TMPRSS2, inhibit SARS-CoV-2 replication by attenuating virus assembly/release, and protect SARS-CoV-2-induced lung damage by suppressing immune response and inflammation development. Preclinical studies and clinical trials with slow-releasing H[SUB]2[/SUB]S donor(s) or the activators of endogenous H[SUB]2[/SUB]S-generating enzymes should be considered as a preventative treatment or therapy for COVID-19.
Keywords: ACE2; COVID-19; H2S; SARS-CoV-2; TMPRSS2.